Recombinant Proteins Manufacturing Services Market Report 2026

The recombinant proteins manufacturing services market size has grown rapidly in recent years. It will grow from $3.7 billion in 2025 to $4.21 billion in 2026 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to growth in biologics research programs, increasing academic protein studies, expansion of contract manufacturing models, rising monoclonal antibody development, historic growth in biotech startups.

The recombinant proteins manufacturing services market size is expected to see rapid growth in the next few years. It will grow to $7.12 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to increasing pipeline of protein therapeutics, rising outsourcing by pharma companies, higher demand for scalable bioprocessing, expansion of clinical stage biologics, growing need for regulatory compliant facilities. Major trends in the forecast period include expansion of outsourced protein production, growth in custom expression services, rising demand for GMP protein manufacturing, integrated end to end service models, higher use of single use bioprocess systems.

The rising demand for biopharmaceuticals and biosimilars is expected to drive the growth of the recombinant proteins manufacturing services market in the coming years. Biopharmaceuticals and biosimilars refer to biologic drugs and their highly similar counterparts that are used to treat chronic, rare, and complex diseases, including cancer, autoimmune disorders, and metabolic conditions. Demand for biopharmaceuticals and biosimilars is increasing due to the growing prevalence of chronic and life-threatening diseases, advancements in biologic drug development, and expanding patient access to targeted therapies across major healthcare markets. Recombinant proteins manufacturing services support the development and commercialization of biopharmaceuticals and biosimilars by offering scalable, high-quality, and regulatory-compliant production of protein-based therapeutics, enabling pharmaceutical and biotechnology companies to accelerate development timelines and ensure consistent product supply. For instance, according to GOV.UK, a UK-based government website, companies operating within the biopharmaceutical subsector reported a total turnover of $135.5 billion (£98.9 billion) during the 2023/2024 period, representing an increase of 15% compared to the previous year. Therefore, the growing demand for biopharmaceuticals and biosimilars is contributing to the growth of the recombinant proteins manufacturing services market.

Key companies operating in the recombinant proteins manufacturing services market are focusing on technological advancements in high-yield protein expression and optimization techniques, such as research-grade and scalable mammalian recombinant protein manufacturing capabilities, to improve production efficiency, enhance protein quality, shorten development timelines, and increase flexibility in meeting diverse biopharmaceutical development requirements. Research-grade and scalable mammalian recombinant protein manufacturing capabilities refer to advancements in cell culture systems, expression technologies, and process controls that enable the efficient production of high-quality recombinant proteins at small research scales while allowing a smooth transition to larger manufacturing volumes. For example, in September 2024, Axio BioPharma, a U.S.-based biotechnology company, launched recombinant protein manufacturing services to support research-grade monoclonal antibody production and scalable mammalian protein expression solutions. The recombinant protein manufacturing services platform offers research-grade and scalable mammalian protein production capabilities that support high-quality monoclonal antibody and recombinant protein expression for early-stage development. With flexible production volumes ranging from small laboratory-scale batches to scalable systems, the platform enables reliable protein output while maintaining consistency and biological activity.

In April 2024, Sino Biological Inc., a China-based provider of recombinant proteins, antibodies, antigens, assay kits, and life science research reagents, acquired SignalChem Biotech Inc. for an undisclosed amount. With this acquisition, Sino Biological aimed to strengthen its global presence and expand its product portfolio by enhancing its capabilities in kinase biology, signal transduction research, and drug discovery support, while deepening access to specialized enzymatic tools for pharmaceutical and biotechnology customers. SignalChem Biotech Inc. is a Canada-based company that offers custom recombinant protein manufacturing services as part of its expertise in bioactive enzymes and cell signaling proteins.

Major companies operating in the recombinant proteins manufacturing services market are Thermo Fisher Scientific Inc., Lonza Group Ltd., Charles River Laboratories International Inc., Catalent Inc., Samsung Biologics Co. Ltd., Recipharm AB, Bio-Techne Corporation, FUJIFILM Diosynth Biotechnologies, AGC Biologics A/S, WuXi Biologics (Cayman) Inc., KBI Biopharma Inc., GenScript Biotech Corporation, Rentschler Biopharma SE, Abzena Ltd., ProBioGen AG, NorthX Biologics AB, Creative Biolabs Inc., evitria AG, Boster Biological Technology Co. Ltd., Icosagen Group AS.

Tariffs on bioreactor equipment, chromatography systems, and specialized lab consumables are raising capital and operating costs in recombinant protein manufacturing services. Import duties on purification resins and single use assemblies are affecting downstream processing segments most strongly. Service providers in regions dependent on imported bioprocess hardware, especially in Asia Pacific and parts of Europe, face margin pressure. These cost increases are being passed partially to clients through higher service fees. At the same time, tariffs are encouraging regional sourcing of equipment and local supplier development. This is strengthening domestic manufacturing ecosystems. It is also driving investment in locally produced bioprocess components.

The recombinant proteins manufacturing services market research report is one of a series of new reports that provides recombinant proteins manufacturing services market statistics, including recombinant proteins manufacturing services industry global market size, regional shares, competitors with a recombinant proteins manufacturing services market share, detailed recombinant proteins manufacturing services market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant proteins manufacturing services industry. This recombinant proteins manufacturing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Recombinant proteins manufacturing services are outsourced offerings that facilitate the production of proteins generated through recombinant DNA technology in controlled laboratory and industrial environments. These services include gene cloning, protein expression, purification processes, and quality assurance testing for research, clinical, and commercial uses. They allow organizations to utilize specialized skills, facilities, and regulatory-compliant production methods without establishing internal manufacturing operations.

The major service types of recombinant protein manufacturing include process development, upstream manufacturing, downstream manufacturing, analytical development and quality control, and finishing and lyophilization. Process development involves designing and optimizing production processes to efficiently produce recombinant proteins with the desired quality and yield. These services cover different protein types, including monoclonal antibodies and antibody fragments, vaccines and viral proteins, enzymes and growth factors, hormones and cytokines, and other therapeutic and diagnostic proteins, and utilize various host cells such as mammalian, bacterial, insect, yeast, and fungal cells. They are applied in therapeutics, research and development, diagnostics, and other areas, serving end users including pharmaceutical and biotechnology companies and academic and research institutes.

The recombinant proteins manufacturing services market includes revenues earned by entities through cell line development, protein expression and purification, quality control and analytical testing, regulatory compliance and documentation, and custom manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.